Study Details and Context
A 2026 study published in *Skeletal Radiology* evaluated the diagnostic accuracy of vertebral bone quality (VBQ) and femoral bone quality (FBQ) scores as potential imaging markers for osteoporosis screening compared to dual-energy X-ray absorptiometry (DXA). The research aimed to assess whether MRI-derived metrics could serve as opportunistic tools for identifying low bone mineral density (BMD) in at-risk populations. The study included 248 participants aged 40 years and older (women) or 50 years and older (men) who underwent both DXA and lumbar spine, hip, or pelvic MRI within 60 days. All MRIs were conducted at 1.5 T, and VBQ and FBQ scores were calculated using manually placed circular regions of interest (ROIs). The authors emphasized the need for alternative screening methods, as DXA remains the gold standard but may not always be accessible or prioritized in clinical settings.
Study Methods and Metrics
The study employed a retrospective cross-sectional design, analyzing data from participants who had both DXA and MRI scans. VBQ was calculated from lumbar spine MRI images, while FBQ was derived from coronal T1-weighted images using two approaches: femoroacetabular joint fluid (FBQfa) and cerebrospinal fluid (FBQcsf). Interobserver reproducibility was assessed using intraclass correlation coefficients (ICCs), and correlations with DXA T-scores were analyzed via Pearson coefficients. Receiver operating characteristic (ROC) curves were used to evaluate diagnostic performance for osteoporosis. The study excluded individuals with a history of lumbar spine surgery and focused on a population with higher osteoporosis risk to enhance statistical power. The authors noted that prior research often targeted younger, healthier populations or surgical cohorts, whereas this study aimed to address a more clinically relevant group.
Key Findings and Correlations
VBQ demonstrated excellent interobserver reliability (ICC = 0.922) and a weak-to-moderate negative correlation with DXA T-scores (r = −0.307; p < 0.001). VBQ values increased across DXA-defined bone density categories, with an optimal cutoff of 3.61 for osteoporosis (AUC = 0.71). In contrast, FBQcsf showed high reproducibility (ICC = 0.874) but no significant correlation with DXA T-scores (p = 0.151). However, FBQcsf distinguished normal BMD from osteopenia (p = 0.002) and, after adjusting for age and sex, differentiated osteopenia from osteoporosis (p = 0.011). The authors highlighted that while VBQ correlates with DXA, FBQcsf may detect early marrow-related changes not fully captured by traditional BMD measurements. Both metrics showed potential as complementary tools for opportunistic osteoporosis screening, though further validation is needed.
Limitations and Clinical Implications
The study acknowledges several limitations, including its retrospective design and reliance on a specific population of older adults without prior lumbar spine surgery. The authors note that the weak correlation between FBQcsf and DXA T-scores suggests it may measure different aspects of bone health, such as marrow composition, rather than BMD directly. Additionally, the need for further validation in larger, more diverse cohorts was emphasized. While VBQ shows promise as an exploratory screening marker, the authors caution against replacing DXA with MRI-based metrics without additional research. The study also highlights the importance of considering age and sex adjustments when interpreting FBQcsf results. These findings underscore the potential for MRI to augment existing osteoporosis screening protocols but do not establish it as a standalone alternative to DXA.
Conclusion and Future Directions
The study concludes that VBQ can serve as an opportunistic exploratory screening marker for low BMD, while FBQcsf may identify early marrow-related changes not fully reflected by DXA. However, both metrics require further validation before clinical implementation. The authors suggest that MRI-derived scores could complement DXA in populations where access to or prioritization of BMD testing is limited. Future research should focus on prospective studies across broader demographics and settings to confirm these findings. The study also emphasizes the need to differentiate between BMD measurements and other bone quality parameters, as MRI may capture aspects of bone health not fully addressed by current standards. While the results are promising, they do not yet support a shift away from DXA as the primary diagnostic tool for osteoporosis.